5-(4-isopropylsulfonylphenyl)-3-(4-phenylpiperazin-l-yl)pyrazin-2-amine | 1349151-55-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 5-(4-isopropylsulfonylphenyl)-3-(4-phenylpiperazin-l-yl)pyrazin-2-amine
• 英文别名: 3-(4-Phenylpiperazin-1-yl)-5-(4-propan-2-ylsulfonylphenyl)pyrazin-2-amine
• CAS: 1349151-55-8
• 化学式: C₂₃H₂₇N₅O₂S
• 分子量: 437.566
• InChiKey: BQXTYCHPDDPPHA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE
  申请人：Charrier Jean-Damien

  公开号：US20120035408A1

  公开（公告）日：2012-02-09

  The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula V: wherein the variables are as defined herein.

  本发明涉及用作ATR蛋白激酶抑制剂的吡嗪和吡啶化合物。本发明还涉及包含该发明化合物的药学上可接受的组合物；使用该发明化合物治疗各种疾病、障碍和病症的方法；制备该发明化合物的过程；制备该发明化合物的中间体；以及在体外应用中使用该化合物的方法，例如研究生物和病理现象中的激酶、通过此类激酶介导的细胞内信号转导途径的研究以及新的激酶抑制剂的比较评估。本发明化合物的化学式为V，其中变量的定义如本文所述。
• US9062008B2
  申请人：——

  公开号：US9062008B2

  公开（公告）日：2015-06-23
• [EN] COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE<br/>[FR] COMPOSÉS UTILISABLES EN TANT QU'INHIBITEURS DE LA KINASE ATR
  申请人：VERTEX PHARMA

  公开号：WO2011143423A2

  公开（公告）日：2011-11-17

  The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula (V): (Formula (v)) wherein the variables are as defined herein.